# Heidi Health Trading

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/heidi-health-trading-pty

- Industry: Healthcare IT
- Headquarters: Melbourne, Australia
- Website: www.heidihealth.com
- Total disclosed funding: $181M
- Latest round: Series C (Sep 22, 2026)
- Investors on record: 14

## About

Based in Melbourne, Victoria, Australia, and co-founded by Thomas Kelly (CEO), Yu Lio (CTO), and Waleed Mussa (CFO) in 2019, Heidi Health Trading Pty Limited formerly known as Oscer Enterprises Pty Limited operates as a provider of an artificial intelligence-based platform solution to medical firms. In September 2026, Heidi Health Trading Pty Limited raised AUD 335 million in growth funding led by General Catalyst Partners. In September 2026, Heidi Health Trading Pty Limited raised AUD 140 million in series C funding led by investor Blackbird, with participation from other investors LocalGlobe, Point72, and Headline. The round was part of a larger AUD 475 million series C and growth funding.

The company through its platform, Heidi, bridges the gap between patients and healthcare providers by streamlining medical documentation and eliminating the hassle of managing referrals, prescriptions, and test results online. Also, Heidi offers an AI-powered interface that empowers patients to take control of their health journey and access care on their own terms, through the features like chat-based consults, telehealth options, and in-person appointments. Additionally, Heidi optimizes clinic operations, reducing idle time, and minimizing administrative burdens, which results in increased revenue potential, improved work-life balance for doctors, and enhanced patient satisfaction. The platform's innovative approach to healthcare delivery positions it as a transformative tool for both patients and medical practitioners. In September 2026, Heidi Health Trading Pty Limited raised AUD 140 million in series C funding led by returning investor Blackbird, with participation from other returning investors LocalGlobe, Point72, and Headline. The round was part of a larger AUD 475 million series C and growth funding.


The company will use the September 2026 funding to develop AI agents that can complete clinical tasks under supervision, expand global sales operations, and support clinical testing and regulatory submissions.

## Funding rounds

- Series C, Sep 22, 2026, $100M — Headline, Blackbird, LocalGlobe, Point72
- Series B, Oct 3, 2025, $65M — Headline, Blackbird, LocalGlobe, Point72 Asset Management
- Series A, Dec 17, 2024, $9.8M — Menlo Ventures, Headline, HESTA, Blackbird, Archangel Ventures, LocalGlobe, Possible Ventures
- Series A, Aug 25, 2023, $2.6M — HESTA, Hostplus, Blackbird, Archangel Ventures, Possible Ventures, Wormhole Capital, Saniel Ventures
- Seed, Jul 16, 2021, $3.7M — Blackbird, Archangel Ventures, Inventures, January Capital

## Investors

- Blackbird (https://capitalatlas.ai/funds/blackbird) — Seed, Series A, Series B, Series C
- Archangel Ventures (https://capitalatlas.ai/funds/archangel-ventures) — Seed, Series A
- Inventures (https://capitalatlas.ai/funds/inventures) — Seed
- January Capital (https://capitalatlas.ai/funds/january-capital) — Seed
- HESTA — Series A
- Hostplus — Series A
- Possible Ventures — Series A
- Wormhole Capital (https://capitalatlas.ai/funds/wormhole-capital) — Series A
- Saniel Ventures (https://capitalatlas.ai/funds/saniel-ventures) — Series A
- Menlo Ventures (https://capitalatlas.ai/funds/menlo-ventures) — Series A
- Headline (https://capitalatlas.ai/funds/headline) — Series A, Series B, Series C
- LocalGlobe (https://capitalatlas.ai/funds/localglobe) — Series A, Series B, Series C
- Point72 Asset Management — Series B
- Point72 (https://capitalatlas.ai/funds/point72) — Series C